Viridian Therapeutics, Inc.\DEVRDN

時価総額
PER
2014年
12月31日
2015年
12月31日
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
2023年
12月31日
Net loss-8-11-13-27-33-42-111-79-130-238
Issuance of common stock under license agreement-0----68-6
Share-based compensation expense4322444142067
Amortization of Debt Issuance Costs and Discounts--------00
Depreciation and amortization0000000001
Accretion and amortization of premiums and discounts on available-for-sale securities----00-0-1011
Realized gain on investments-------0--
Loss on sale of equipment--------0--0
Net loss on extinguishment of debt---71,000-------0
Non-Cash Lease Expense--------000
Debt Extinguishment Expense---------1
Prepaid expenses and other assets-0-0-01-0-00132
Accounts payable----0-01-0212-12
Accrued and other liabilities----2115185
Unbilled revenue---------0-
Deferred revenue-------1-0-0
Loss on sale of equipment--------0--0
Non-Cash Lease Expense--------000
Other non cash items-------0---0
Prepaid expenses and other assets-0-0-01-0-00132
Accounts payable----0-01-0212-12
Accrued and other liabilities----2115185
Unbilled revenue---------0-
Deferred revenue-------1-0-0
Net cash used in operating activities-2-7-7-28-27-36-30-55-94-184
Purchases of short-term investments-------188223408
Proceeds from sales and maturities of short-term investments--------109315
Proceeds from sale of property and equipment-------0--
Purchases of property and equipment0000000011
Net cash used in investing activities-0-0-01-3028-50-74-115-94
Proceeds from Issuance of Common Stock---------15
Common Stock------17197
Preferred Stock------5135
Payment of issuance costs-----0----
Proceeds from Issuance of Private Placement---------76
Proceeds from Issuance of Convertible Preferred Stock------91-44-
Common Stock------17197
Preferred Stock------5135
Payment of issuance costs-----0----
Proceeds from Warrant Exercises--------12
Proceeds from Issuance of Convertible Preferred Stock------91-44-
Proceeds from Issuance of Secured Debt--------515
Proceeds from Warrant Exercises--------12
Payment of debt issuance costs--------0-
Proceeds from Issuance of Secured Debt--------515
Proceeds from Stock Options Exercised---000-1319
Payment of debt extinguishment costs---------1
Proceeds from Stock Plans-------001
Payment of debt issuance costs--------0-
Net cash provided by financing activities713-052420101125322226
Proceeds from Stock Options Exercised---000-1319
Proceeds from Stock Plans-------001
Net cash provided by financing activities713-052420101125322226
Net increase (decrease) in cash and cash equivalents------821-4113-53
Interest paid----010-01
Capital Expenditures Incurred but Not yet Paid-------00-
Amortization Of Stock Issuance Costs------000-
Stock Issuance Costs Included In Accrued Liabilities---------0
Stock Issuance Costs Included In Accounts Payable---------0
Notes Reduction---------5
Notes Issued---------5
Amortization Of Stock Issuance Costs------000-